Atovaquone, proguanil (Hetovanil)
Atovaquone, proguanil
Hetero Drugs South Africa (Pty) Ltd
Registration
- Applicant
- Hetero Drugs South Africa (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Hetovanil 62,5/25 MG Each tablet contains ATOVAQUONE 62,5 mg and PROGUANIL HCL 25,0 mg | 62,5/25 mg | 48052648/20.2.6/0526 | Registered | Not determined | None |
| Hetovanil 250/100 MG Each tablet contains ATOVAQUONE 250,0 mg and PROGUANIL HCL 100,0 mg | 250/100 mg | 48052748/20.2.6/0527 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Atovaquone
- when co-formulated with proguanil and intended and labelled for the chemoprophylaxis of malaria in those weighing 11 kilograms or more. (S2)
Consolidated Schedules 06 July 2026, lines 5380 to 5383
S4: Proguanil
- when co-formulated with atovaquone and intended and labelled for the chemoprophylaxis of malaria in those weighing 11 kilograms or more. (S2)
Consolidated Schedules 06 July 2026, lines 7661 to 7664
S2: Atovaquone
- when co-formulated with proguanil and intended and labelled for the chemoprophylaxis of malaria in those weighing 11 kilograms or more. (S4)
Consolidated Schedules 06 July 2026, lines 1622 to 1625
S2: Proguanil
- when co-formulated with atovaquone and intended and labelled for the chemoprophylaxis of malaria in those weighing 11 kilograms or more. (S4)
Consolidated Schedules 06 July 2026, lines 2579 to 2582
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.